Sign up to save your podcasts
Or
Share Riggins - Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends...
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Riggins - Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends...
Full text - http://bit.ly/2yTX4uJ
Oncotarget | Interview with Dr. Gregory J. Riggins from the Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA talking about their featured cover paper published in Volume 8 Issue 46 titled "Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients".
Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N
www.Oncotarget.com
View all episodes
By Oncotarget Podcast
5
44 ratings
Full text - http://bit.ly/2yTX4uJ
Oncotarget | Interview with Dr. Gregory J. Riggins from the Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA talking about their featured cover paper published in Volume 8 Issue 46 titled "Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients".
Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N
www.Oncotarget.com